C3

PHASE 3 SUMMARY OF MRID 00104250:

PRIMARY DERMAL IRRITATION IN THE RABBIT

STUDY # 6818A

FLUMETRALIN

GUIDELINE REFERENCE:

81-5 PRIMARY DERMAL IRRITATION IN THE RABBIT

SUMMARY PREPARED BY:

JACQUELINE GILLIS, Ph.D.

MERRILL TISDEL

14 SEPTEMBER 1990

ORIGINAL STUDY PREPARED BY:

FOOD AND DRUG RESEARCH LABORATORIES, INC.

WAVERLY, NEW YORK

C3

STATEMENT OF NO DATA CONFIDENTIALITY CLAIMS

No claim of confidentiality is made for any information contained in this study on the basis of its falling within the scope of FIFRA §10(d)(1)(A), (B), or (C).

Company: CIBA-GEIGY Corporation (Typed Name)

Company Agent: Thomas Parshley (Typed Name)

Title: Senior Reg. Specialist

Signature: _____ Date: _____

These data are the property of the Agricultural Division of CIBA-GEIGY Corporation, and as such, are considered to be confidential for all purposes other than compliance with FIFRA §10. Submission of these data in compliance with FIFRA does not constitute a waiver of any right to confidentiality which may exist under any other statute or in any other country.

C3

FDRL Study No. 6818A

Primary Skin Irritation Study in Rabbits
of CGA-41065 Technical

GLP Compliance Statement

I hereby certify that this study was performed in compliance with regulations for Good Laboratory Practice (GLP) as described by FDA (21 CFR Part 58) and although completed and reported prior to promulgation of the EPA GLP, essentially in compliance with EPA (40 CFR Part 160).

James Laveglia, ~~Ph.D.~~, President
for Study Director

9/6/90
Date

This study does not meet the requirements for 40 CFR Part 160 since it was conducted prior to the issuance of the EPA Good Laboratory Practice Standards. It was conducted according to the FDA Good Laboratory Practice Standards as indicated above.

Submitter/Sponsor of Study:

Merrill Tisdel
Agricultural Division
CIBA-GEIGY Corporation
Greensboro, North Carolina

C3

Certification of Availability of Raw Data

I hereby certify that the submitter possesses or has access to the raw data used in or generated by the study summarized in this document.

Submitter's Representative:

Signature/Date: Merrill Tisdel 10.15.90

Typed Name: Merrill Tisdel

Title: Toxicologist

Certification of Accuracy of Summary and Adequacy of the Study

I certify, in compliance with FIFRA section 4(e)(1)(A), that this summary accurately represents the data presented in the report(s) of this study cited by MRID, and that this study fully satisfies all pertinent requirements of the OPP Guideline it addresses.

Submitter's Representative:

Signature/Date: Merrill Tisdel 10.15.90

Typed Name: Merrill Tisdel

Title: Toxicologist

R406MT0628MG

C3

Subdivision F
Guideline Ref. No. 81-5
December 24, 1989

81-5 Primary Dermal Irritation Study

ACCEPTANCE CRITERIA

Does your study meet the following acceptance criteria?

1. Y — Technical form of the active ingredient tested. (for reregistration only)
2. N — Study not required if material is corrosive or has a pH of ≤ 2 or ≥ 11.5.
3.* Y — 6 adult animals.
4. Y — Dosing, single dermal.
5. N — Dosing duration 4 hours.
6. Y — Application site shaved or clipped at least 24 hour prior to dosing.
7. Y — Application site approximately 6 cm^2.
8. Y — Application site covered with a gauze patch held in place with nonirritating tape
9. Y/N — Material removed, washed with water, without trauma to application site
10. Y/N — Application site examined and graded for irritation at 1, 24, 48 and 72 hr, then daily until normal or 14 days (whichever is shorter).
11.* Y — Individual observations for the entire day of dosing.
12.* Y — Individual daily observations.

Criteria marked with a * are supplemental and may not be required for every study.

C3

IDENTIFICATION OF TEST MATERIAL

Chemical Name

CAS Name:	N-(2-Chloro-6-fluorobenzyl)-N-ethyl-α,α,α,-trifluoro-2,6-dinitro-p-toluidine
	or
	2-Chloro-N-[2,6-dinitro-4-(trifluoromethyl)phenyl]-N-ethyl-6-fluorobenzenemethanamine
Common Name:	Flumetralin
Trade Name:	Prime +®
CIBA-GEIGY Code Number:	CGA-41065
CAS Registry Number:	62924-70-3
EPA Shaughnessy Number:	Unknown

Chemical Structure:



Percent Active Ingredient

92% minimum

Flumetralin: 81-5: Primary Dermal Irritation

1. The test article was Flumetralin (CGA-41065) Technical, a bright orange crystalline substance, FL-810009, purity 96.4%.

2. The test article is not corrosive, dose not have a pH less than 2.0 or greater than 11.5, and does not have a dermal LD_{50} less than 200 mg/kg.

3. Four male and two female New Zealand white rabbits were tested.

4. The dose was administered as a single application of 0.5 g of actual test material.

5. The duration of dermal exposure was 24 hours.

6. The animals were prepared on the day prior to treatment by clipping a portion of the back and flank of each animal free of hair. Immediately prior to application of the test article, the right dorsal area was abraded with the point of a disposable hypodermic needle. The abrasions penetrated the stratum corneum but did not disturb the derma or cause bleeding. The left dorsal side was left intact.

7. The area of each of the four test sites (two intact and two abraded) was approximately 6-9 cm^2.

8. A 1" x 1" surgical gauze patch covered each test site and was secured in place with masking tape. The application sites were covered with an occlusive wrap consisting of a layer of plastic wrap, a protective cloth, and a stockinette sleeve. The wrap was held in place with masking tape.

9. The occlusive binders and patches were removed at the end of the exposure period. The sites were then gently wiped with clean gauze to remove as much non-absorbed test article as possible.

10. The test sites were examined and graded for irritation at 30 minutes and 48 hours after patch removal.

11. Animals were not specifically observed for pharmacologic and/or toxicologic effects on the day of dosing, although the protocol indicates that extraordinary observations would be recorded. No extraordinary observations were noted on the day of dosing.

12. For intact/non-abraded sites, dermal irritation scores at 30 minutes and 48 hours after patch removal averaged 3.7 and 1.6, respectively. For abraded sites, dermal irritation scores at 30 minutes and 48 hours after patch removal averaged 4.0 and 2.0, respectively. Animals were not specifically observed for pharmacologic and/or toxicologic effects on the days following dosing, although the protocol indicates that extraordinary observations would be recorded. No extraordinary observations were noted on the days following dosing.

16. There were no significant changes from the Acceptance Criteria in this study. There were three minor deviations. Under Item 5, the dosing duration was 24 hours rather than four hours. Under Item 9, the application site was wiped but not washed with water. These two deviations are considered to be insignificant because each would be expected to result in more severe irritation. Under Item 10, sites were graded for irritation at approximately 24 and 48 hours after dosing. Because the exposure period was 24 hours, the grading was done at approximately 30 minutes and 48 hours after the end of the dosing period. The toxicity category was assigned on the basis of scores at 48 hours from the end of the dosing period. Scores for all animals decreased dramatically between 30 minutes and 48 hours. It is unlikely that any of the scores would have increased between 48 and 72 hours.

GILLIS:R505SW0921JG/MT